Semax

Semax is a short synthetic peptide related to ACTH, developed in Russia and used there in clinical settings including stroke care. Its published literature is small, largely regional, and rarely independently replicated. It is not approved in the United States or European Union, and evidence for cognitive enhancement in healthy adults is weak.

An evidence-first review of Semax, a peptide marketed for focus and memory: its regional regulatory history, the limits of the published literature, and.

Approved in one region, unstudied in most of the world, and marketed everywhere.

Key takeaways

Where the evidence comes from

Semax has a genuine clinical history, but it is concentrated in one national research and regulatory tradition. That is not automatically a reason to dismiss the findings; it is a reason to note that independent replication under contemporary trial standards is largely absent, which is exactly what the Early Research label describes.

The cognition claim

Cognitive enhancement in healthy adults is one of the hardest claims to establish. It requires blinded, placebo-controlled designs with validated outcome measures and adequate numbers, because expectation effects on subjective focus are large. That literature does not exist for Semax.

Supply reality

Semax sold internationally is a grey-market product. Nasal sprays carry the same identity and sterility problems as injectables, with the added question of what else is in the solution.

Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.

Frequently asked questions

Is Semax approved anywhere?

It is registered in Russia for specified indications. It is not approved by the FDA or EMA.

Does it improve focus in healthy people?

There is no adequate blinded, placebo-controlled trial evidence supporting that in healthy adults.

Is a nasal spray safer than an injection?

It avoids injection-related infection risk but does not resolve identity, purity or sterility concerns with unregulated products.

Related on Beiing

Sources

  1. PubMed - National Library of Medicine - NIH
  2. ClinicalTrials.gov - U.S. National Library of Medicine
  3. National Institutes of Health (NIH) - NIH

Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.